-
In the first half of the year, ordinary people had a revenue of 7.46 billion, 11 mergers and acquisitions, and a large volume of self-owned brands
Time of Update: 2021-09-05
Layout: 1,290 new stores, 11 mergers and acquisitions with a value of over 570 million As of June 30, ordinary people’s business covered 22 provinces across the country, with a total of 7680 stores, including 5682 directly-operated stores and 1998 franchised stores.
-
Announcement of the list of top 100 pharmacies and drug approvals in the country
Time of Update: 2021-09-05
7% of the total national pharmaceutical market during the same period, a year-on-year increase of 0.
From 2016 to 2020, the top 100 pharmaceutical retail companies accounted for an increasing market share.
-
This CRO "rolled over" several times: Falsified clinical trial data was sent to prison by the FDA
Time of Update: 2021-09-05
On April 28, the FDA issued a non-compliance notice to Acceleron Pharma, the sponsor who failed to submit the necessary information for clinical trials to the federal registration agency, and warned that it may face fines .
-
INSBio's IN10018 treatment of platinum-resistant ovarian cancer was approved by the U.S. FDA for fast track
Time of Update: 2021-09-05
The clinical data of preclinical and phase Ib/II studies of Yingshi Biologics shows that IN10018 combined with chemotherapy has a significant synergistic anti-tumor effect in patients with platinum-resistant ovarian cancer .
-
Wang Guihua, Independent Director of Watson Pharmaceuticals, resigns by-election for Du Shouying as a candidate
Time of Update: 2021-09-05
Wang Guihua applied to resign as an independent director of the company’s second board of directors, chairman of the second board of directors’ remuneration and appraisal committee, member of the audit committee of the second board of directors, and member of the nomination committee of the second board of directors.
-
Pfizer and Flynn Pharmaceuticals accused of manipulation of prices of epilepsy drugs by British CMA
Time of Update: 2021-09-05
CompilationFan DongdongA few days ago, the British Competition and Markets Authority (CMA) accused Pfizer and Flynn Pharmaceuticals of violating antitrust rules and increasing the prices of anti-epileptic treatments, resulting in them charging the British National Health Service (NHS) excessive treatment fees .
-
Mission blessing!
Time of Update: 2021-09-05
At that time, Wang Zhenyi's all-trans retinoic acid treatment method was still only in the test tube experiment stage.
-
Sagimet, a partner of Songli, completes the first phase IIb clinical administration of patients with moderate to severe fibrosis NASH
Time of Update: 2021-09-05
On August 16, Gerry Pharmaceuticals announced that its partner Sagimet Biosciences has completed the first patient administration of its non-alcoholic steatohepatitis (NASH) phase IIb clinical trial (FASCINATE-2) .
FASCINATE-2 is a randomized, double-blind, placebo-controlled phase IIb clinical trial that enrolled approximately 330 NASH patients with moderate to severe fibrosis (F2-F3) .
-
U.S. FDA grants Vivet/Pfizer VTX-801 fast track qualification
Time of Update: 2021-09-05
VTX-801 is a new type of research gene therapy, which will be evaluated in the Phase 1/2 GATEWAY trial (NCT04537377) to determine the safety, tolerability and pharmacological activity of a single intravenous infusion in the treatment of adults with Wilson disease .
-
Haisco is out!
Time of Update: 2021-09-05
Recently, Haisco’s R&D pipeline has frequently appeared: the first imitation perindopril indapamide tablet was approved for marketing, the new class 1 drug HSK16149 capsules and HSK21542 injection
-
National talks varieties soared by 6000%! 27 Class 1 new drugs to challenge Hengrui and Renfu to fight again
Time of Update: 2021-09-05
In recent years, with the improvement of the R&D capabilities of domestic pharmaceutical companies and the acceleration of review and approval, more and more new drugs have entered the market.
-
British Silicon Intelligence and Yosen Jianheng reached a cooperation to use AI to accelerate the research and development of small molecule innovative drugs
Time of Update: 2021-09-05
Text|Pharmaceutical Mission HillsRecently, Insilico Medicine, an artificial intelligence drug research and development company, and Usynova announced a strategic cooperation .
(The original text has been deleted)
-
Promoting the whole province: only one certificate is needed to open a pharmacy
Time of Update: 2021-09-05
Pharmacies in Liaoning province will implement "multiple certificates in one"Pharmacies in Liaoning province will implement "multiple certificates in one"Recently, the Liaoning Provincial Food and Drug Administration issued the "Implementation Opinions on Promoting the Work of "Multi-license Integration" in Pharmaceutical Retail Enterprises (Draft for Solicitation of Comments)" (hereinafter referred to as "Opinions") to simplify the approval procedures and improve the efficiency of approval .
-
Director Wang Damei and supervisor Yang Jinhui of Ganli Pharmaceutical resign Chen Wei and Zhang Tao as candidates
Time of Update: 2021-09-05
Wang Damei resigned as a director of the company due to work planning and other personal reasons.
In addition, the board of supervisors of the company received a "resignation report" submitted by supervisor Yang Jinhui.
-
Treat chronic hepatitis B! GSK antisense oligonucleotide drug approved for clinical use
Time of Update: 2021-09-05
Therefore, after stopping the drug, the recurrence rate of chronic hepatitis B is very high,GSK3228836 is an antisense oligonucleotide that can specifically recognize the mRNA used to express viral antigens (pathogenic proteins) in liver cells infected with HBV, and inactivate viral mRNAs by mobilizing the liver’s own enzymes to inhibit viral proteins HBsAg levels in order to achieve the functional purpose of curing hepatitis B .
-
WuXi Giant Noreki Oronza injection is about to be approved or become the second CAR-T product in China
Time of Update: 2021-09-05
FinishingRheeToday, China's National Food and Drug Administration (NMPA) announced that the listing application of WuXi's Noreji Orencil injection (relma-cel) has entered the "pending approval" status and is expected to be approved in China in the near future .
-
Another AD drug!
Time of Update: 2021-09-05
In June of this year, Aduhelm developed by Biogen and Eisai was approved by the FDA, becoming the first approved drug for Alzheimer's disease in the United States in the past 20 years .
-
Full moon baby compensates 10,000 yuan for mistaking prescription drugs
Time of Update: 2021-09-05
A baby who was just full month old was sent to the doctor because the pharmacy prescribed the wrong dosage of Chinese medicine and showed adverse symptoms after taking the medicine. The pharmacy comp
-
Drug Administration: Nanchang Huayi's first batch of medical devices is being recalled
Time of Update: 2021-09-05
On August 19, the State Food and Drug Administration issued an announcement to notify Nanchang Huayi of its voluntary recall of some of its products in violation of regulations .
The company immediately initiated the recall procedure for this batch of products .
-
Eisai Perampanel approved for 2 new indications
Time of Update: 2021-09-05
In September 2019, Perampanel was approved for marketing in China for the add-on treatment of patients with partial epilepsy (with or without secondary generalized seizures) aged 12 years and older .
